The Week in Review: Sep 14 – Sep 21, 2018

Friday, Sep 21, 2018 News Recap: New Chinese HBV Pamphlets from HepCBC There are some new HBV pamphlets from HepCBC in Chinese: HBV Chinese (Traditional) and HBV Chinese (Simplified). View the rest of our new and recently updated pamphlets here: http://hepcbc.ca/publications/pamphlets-posters/ Events: Tuesday, Sept. 25th approximately 11 am - 3 pm is the Downtown Eastside ALLEY Health Fair, location is intersection of Hastings and Columbia S...

The Week in Review: Sep 7 – Sep 14, 2018

Friday, Sep 14, 2018 News Recap: Showcasing HepCBC’s Translation Team Canada’s various immigrant communities have been particularly devastated by viral hepatitis, as hepatitis B or hepatitis C are often endemic in Asia, Eastern Europe, Africa, and South America. Language and cultural barriers may lead to sufferers not knowing about, seeking or receiving potentially life-saving treatment. To help out, HepCBC has started translating its standard Hep B...

Showcasing HepCBC’s Translation Team

Canada’s various immigrant communities have been particularly devastated by viral hepatitis, as hepatitis B or hepatitis C are often endemic in Asia, Eastern Europe, Africa, and South America. Language and cultural barriers may lead to sufferers not knowing about, seeking or receiving potentially life-saving treatment. To help out, HepCBC has started translating its standard Hep B and Hep C pamphlets into some of the non-English languages of British Colum

HepCBC Volunteers Return to the Kitchen Table

September 1, 2018 saw HepCBC “return to the kitchen tables” of its volunteers for its operations. We have had to close both our offices and lay off all staff at least for the next few months. This was due to a temporary funding shortage, and all services continue without interruption, including our website and social media, our toll-free phone line 1-844-268-2118 (direct dial 250-595-3892), our participation in many community events, prison visitations, p

New test aims to help identify thousands in B.C. unknowingly living with hepatitis C

A new pilot project seeking to screen adult British Columbians is hoping to change the situation. Five London Drugs locations in the Lower Mainland are offering screening through a new $24 finger-prick test called OraQuick HCV that can turn results around in just 20 minutes. Dr. Alnoor Ramji, a hepatitis C specialist and clinical associate professor of medicine at UBC, said the program is designed to help identify people unknowingly living with the vir

The Week in Review: Aug 31 – Sep 7, 2018

Friday, Sep 7, 2018 News Recap: London Drugs Launches Potentially Life-Saving Hepatitis C Screening at Pharmacies in BC Lower Mainland. An innovative and potentially life-saving hepatitis C screening program has launched at five London Drugs locations in the Lower Mainland. Patients can now undertake a simple finger prick test at the pharmacy to check if they have been exposed to hepatitis C virus (HCV) at some point in the past. Hundreds of pati...

London Drugs Launches Potentially Life-Saving Hepatitis C Screening at Pharmacies in BC Lower Mainland

VANCOUVER, British Columbia, Sept. 07, 2018 (GLOBE NEWSWIRE) -- An innovative and potentially life-saving hepatitis C screening program has launched at five London Drugs locations in the Lower Mainland. Patients can now undertake a simple finger prick test at the pharmacy to check if they have been exposed to hepatitis C virus (HCV) at some point in the past. The test, called the OraQuick HCV rapid antibody test, is more than 99% accurate at detecting HCV

Hundreds of patients from Stittsville medical centre tested for hepatitis and HIV

More than 1,500 patients who received treatment at a Stittsville medical centre have been tested for hepatitis B, hepatitis C and HIV by Ottawa Public Health after infection control lapses were discovered earlier this year. The testing revealed that a handful of the patients are currently infected or potentially infected with hepatitis B or C (some need further testing). But a spokeswoman for Ottawa Public Health said they are satisfied those cases are no

Inovio (INO) Initiates Phase I Study on Hepatitis C Vaccine

Inovio Pharmaceuticals, Inc. (INO) along with Korean partner GeneOne Life Science announced that it has dosed the first patient in a phase I study, evaluating its hepatitis C vaccine GLS-6150 to boost immunity in patients. Both companies are jointly developing the world’s first vaccine to prevent hepatitis C infection. Korean pharma company GeneOne Life Science has already started enrolling patients in South Korea and will be responsible for conducting an